Research programme: hepatitis therapeutics - InterMune
Latest Information Update: 13 Apr 2010
At a glance
- Originator InterMune
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis
Most Recent Events
- 13 Apr 2010 Discontinued - Preclinical for Hepatitis in USA (unspecified route)
- 31 Dec 2008 This programme is still in active development